
|

| |
Track this Pro and follow
their portfolio moves with tickerspy™ alerts |
 |
|
 | Baker Bros. Advisors |
| |
Performance |
|
|
|
Similar Pro Portfolios |
|
|
|
Community |
|
| |
Today:
Week:
1-month:
All-time:
|
+1.4%
+6.5%
+17.5%
+104.4%
|
vs S&P 500:
vs S&P 500:
vs S&P 500:
vs S&P 500:
|
+1.8%
+8.9%
+22.0%
+110.0%
|
Data since: Jul-1-2007 Current Portfolio: Q4 2011
|
|
|
|
|
|
|
|
|
Share this Pro on Facebook
Share this Pro on Twitter
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |

 |
Click
a column to sort | Scroll over columns for more information |
|
|
| ARIA |
$17.52 |
+0.25 |
+1.45% |
3,718,008 |
112% |
$2.8B |
- |
132% |
1% |
+43.0% |
$66.2M | 5.4M shares - increase of 4.1M shares
2 Alerts (0 News) - View
|
|
|
| AUXL |
$18.48 |
+0.05 |
+0.27% |
281,046 |
64% |
$892.8M |
- |
36% |
-18% |
-7.3% |
$128.8M | 6.5M shares - No Change
No Alerts/News
|
|
|
| BCRX |
$3.63 |
0.00 |
0.00% |
146,692 |
51% |
$179.4M |
- |
59% |
-39% |
+47.0% |
$13.7M | 5.6M shares - No Change
No Alerts/News
|
|
|
| BMRN |
$38.46 |
-0.32 |
-0.83% |
1,223,828 |
112% |
$4.4B |
- |
62% |
-1% |
+11.9% |
$16.8M | 487.7K shares - increase of 150.3K shares
2 Alerts (0 News) - View
|
|
|
| GEVA |
$38.43 |
-0.43 |
-1.11% |
127,541 |
166% |
$816.1M |
- |
283% |
-5% |
+44.3% |
$164.7M | 6.2M shares - increase of 5.5M shares
No Alerts/News
|
|
|
| GHDX |
$34.34 |
-0.13 |
-0.38% |
217,215 |
132% |
$1.0B |
- |
81% |
-1% |
+35.3% |
$223.0M | 8.8M shares - increase of 918.0K shares
2 Alerts (0 News) - View
|
|
|
| GILD |
$51.58 |
-0.29 |
-0.56% |
6,719,997 |
81% |
$39.1B |
- |
50% |
-9% |
+26.0% |
$118.2M | 2.9M shares - New Holding
1 Alert (0 News) - View
|
|
|
| HALO |
$7.45 |
+0.05 |
+0.68% |
982,208 |
76% |
$837.4M |
- |
34% |
-45% |
-21.7% |
$17.0M | 1.8M shares - decrease of 1.1M shares
No Alerts/News
|
|
|
| INCY |
$23.70 |
+0.95 |
+4.18% |
2,094,895 |
128% |
$3.0B |
- |
102% |
-2% |
+57.9% |
$233.4M | 15.5M shares - increase of 4.5M shares
2 Alerts (0 News) - View
|
|
|
| MDVN |
$88.70 |
+2.58 |
+3.00% |
753,010 |
113% |
$3.2B |
- |
519% |
0% |
+92.4% |
$22.3M | 483.3K shares - No Change
1 Alert (0 News) - View
|
|
|
| PCYC |
$29.31 |
+1.97 |
+7.21% |
1,161,393 |
231% |
$2.0B |
- |
358% |
-0% |
+97.8% |
$118.8M | 8.0M shares - increase of 982.5K shares
3 Alerts (0 News) - View
|
|
|
| RDEA |
$31.75 |
+0.01 |
+0.03% |
402,685 |
23% |
$1.1B |
- |
141% |
-0% |
+88.9% |
$101.1M | 6.0M shares - No Change
1 Alert (0 News) - View
|
|
|
| SGEN |
$20.38 |
+0.31 |
+1.54% |
1,425,122 |
127% |
$2.3B |
- |
66% |
-9% |
+21.9% |
$344.3M | 20.6M shares - No Change
1 Alert (0 News) - View
|
|
|
| SPPI |
$12.14 |
0.00 |
0.00% |
1,942,135 |
70% |
$721.8M |
- |
75% |
-24% |
-17.0% |
$13.3M | 909.9K shares - New Holding
1 Alert (0 News) - View
|
|
|
| VPHM |
$20.04 |
-0.16 |
-0.79% |
931,986 |
45% |
$1.3B |
- |
37% |
-40% |
-26.8% |
$330.0M | 12.0M shares - increase of 1.1M shares
No Alerts/News
|
|
|
|
|
Discuss Baker Bros. Advisors's portfolio
|
|
|
|
| |

|
| |
|
| |

|
| |
Gilead's HIV Quad Pill Wins Backing From FDA Advisers BMY GILD
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - May 11, 02:57PM from (www.bloomberg.com) Gilead Sciences Inc. (GILD)’s experimental HIV pill Quad, the new medicine from the world’s largest maker of AIDS drugs,
Flag
Post a comment
Gilead's Pill Wins U.S. Panel Backing to Prevent HIV GILD
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - May 10, 07:07PM from (www.bloomberg.com) Gilead Sciences Inc. (GILD) won the backing of regulatory advisers for the first approval of a drug to prevent HIV infections in gay and bi-sexual men.
Flag
Post a comment
GlaxoSmithKline to Get Hostile with Offer for Human Genome HGSI AZN RDEA ILMN GSK
Linked by Benzinga.com ( track newsfeed | ignore newsfeed ) - May 09, 09:15AM from (www.benzinga.com) It was revealed on Wednesday that GlaxoSmithKline (NYSE: GSK) is looking to make a hostile takeover move for Human Genome
Flag
Post a comment
Medivation Reports First Quarter Financial Results and Provides Corporate Update MDVN
Linked by marketwire ( track newsfeed | ignore newsfeed ) - May 08, 04:10PM from (www2.marketwire.com) Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the first quarter
Flag
Post a comment
BioMarin to Present at the Baird Growth Stock Conference BMRN
Linked by GlobeNewswire ( track newsfeed | ignore newsfeed ) - May 08, 09:00AM from (www.globenewswire.com) NOVATO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Hank Fuchs,
Flag
Post a comment
BioMarin to Present at the Deutsche Bank Healthcare Conference BMRN
Linked by GlobeNewswire ( track newsfeed | ignore newsfeed ) - May 08, 09:00AM from (www.globenewswire.com) NOVATO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Hank Fuchs,
Flag
Post a comment
SAC Capital Buys More Ariad Pharmaceuticals ARIA
Linked by market folly ( track newsfeed | ignore newsfeed ) - April 30, 10:27AM from (www.marketfolly.com) Steve Cohen's hedge fund SAC Capital filed a 13G with the SEC regarding its ownership stake in Ariad Pharmaceuticals (ARIA).
Flag
Post a comment
Actelion Lung Drug Meets Main Goal in Pivotal Patient Study AMGN GILD
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - April 30, 01:32AM from (www.bloomberg.com) Actelion Ltd. (ATLN)’s experimental lung drug macitentan met the main goal of a late-stage clinical trial, providing the
Flag
Post a comment
ViroPharma Loses Bid for Order Blocking Generic Vancocin AKRX WPI VPHM
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - April 24, 01:07PM from (www.bloomberg.com) ViroPharma Inc. (VPHM) lost a bid for a court order temporarily blocking U.S. Food and Drug Administration marketing approval
Flag
Post a comment
PREMIUM PARTNER CONTENT Featured Biotech Investment Idea Ardea Surges on Buyout AZN RDEA
Posted by bullmarket ( track member | ignore member ) - April 23, 04:21PM In mid-March, we featured a developmental biotech stock we liked called Ardea Biosciences that was developing a drug
Flag
Post a comment
What’s A Better Buyout: Ardea or Amylin? BMY MRK AMLN AZN RDEA
Linked by 24/7 Wall St. ( track newsfeed | ignore newsfeed ) - April 23, 02:54PM from (247wallst.com) Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion
Flag
Post a comment
Nestle Leads Busiest Day for Europe Deals Since Glencore-Xstrata PFE HGSI RDEA
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - April 23, 10:02AM from (www.bloomberg.com) Nestle Leads Busiest Day for Europe Deals
A customer takes a carton of SMA baby milk, produced by Pfizer
Flag
Post a comment
Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial GILD
Linked by Bloomberg ( track newsfeed | ignore newsfeed ) - April 21, 12:16PM from (www.bloomberg.com) Gilead Sciences Inc. (GILD)’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.
Flag
Post a comment
|
|